1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1. Drivers
4.1.1. Growing demand & higher acceptability for innovative therapies
4.1.2. Loss of patent exclusivity of the leading biologics drugs
4.1.3. Increasing capital investment from critical players
4.1.4. The rise in the prevalence of chronic diseases
4.2. Restraints & Challenges:
4.2.1. Stringent regulatory process & Initial high capital investment
4.2.2. Rising control & cost for accessing biologics
4.3. Opportunities
4.3.1. Technology advancements & Drug innovations
5. Global Biologics Market - By Product
5.1. Introduction
5.2. Monoclonal Antibodies
5.3. Vaccines
5.4. Recombinant harmonies/proteins
5.5. Cell Therapy
5.6. Gene Therapy
5.7. Others
6. Global Biologics Market – By Applications
6.1. Introduction
6.2. Cancer
6.3. Infectious Diseases
6.4. Rare Diseases
6.5. Autoimmune Diseases
6.6. Others
7. Global Biologics Market - By Geography
7.1. Introduction
7.2. North America
7.2.1. US
7.2.2. Canada
7.2.3. Mexico
7.2.4. Rest of North America
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Rest of South America
7.4. Europe
7.4.1. France
7.4.2. Germany
7.4.3. U.K
7.4.4. Italy
7.4.4. Rest of Europe
7.5. APAC
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. Australia & New Zealand
7.5.3. Rest of APAC
7.6. Middle East & Africa
7.6.1. Middle East
7.6.2. Africa
8. Company Profiles
8.1. Amgen
8.1.1. Company Overview
8.1.2. Business Segments
8.1.3. Financials (Public Companies)
8.1.4. Developments
8.1.5. SWOT Analysis (Public Companies)
8.2. Abbvie Inc.
8.3. Eli Lilly & Company
8.4. Merck & Co
8.5. Novo Nordisk
8.6. GlaxoSmithKline Plc.
8.7. F. Hoffmann-La Roche Ltd
8.8. Pfizer Inc.
8.9. Sanofi
8.10. Johnson & Johnson
8.11. Allergan Plc.
8.12. Bayer AG
8.13. Teva Pharmaceuticals Industries Limited
8.14. Astellas Pharma Inc.
9. Competitive Landscape
9.1. Market Share Analysis
9.2. Strategies Adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
11. Appendix
11.1 List of Tables
11.2 List of Figures
